

VRL/SEC/EXCHANGE

21.12.2023

<p>National Stock Exchange of India Ltd. 5th Floor, Exchange Plaza Bandra (E), Mumbai- 400 051 Script Code: VENUSREM</p>	<p>BSE Limited 25th Floor, Phiroze Jeejeebhoy Towers Dalal Street, Mumbai Script Code: 526953</p>
--	---

Sub.: Announcement- **Venus Remedies Achieves Marketing Authorizations for Docetaxel in Israel and Cytarabine in Colombia, Expanding Global Impact in Oncology.**

Dear Sir/ Madam,

Venus Remedies, a global leader in pharmaceutical innovation, is excited to announce dual achievements in securing marketing authorisations for three variants of Docetaxel in Israel and Cytarabine 100MG in Colombia. The approved Docetaxel variants (160MG/8ML, 80MG/4ML, 20MG/1ML) and Cytarabine further solidify our commitment to advancing healthcare solutions globally.

Kindly take the above information on your record.

Thank you.

Yours faithfully,
for VENUS REMEDIES LIMITED


Neha
(Company Secretary)

VENUS REMEDIES LIMITED

Corporate Office :
51-52, Industrial Area, Phase- I, Panchkula (Hry.)
134113, India

Regd. Office :
SCO 857, Cabin No. 10, 2nd Floor, NAC, Manimajra,
Chandigarh (U.T.) 160101, India
Website : www.venusremedies.com
www.vmrindia.com
email : info@venusremedies.com
CIN No. : L24232CH1989PLC009705

Unit-I :
51-52, Industrial Area, Phase-I, Panchkula (Hry.) 134113, India
Tel. : +91-172-2933090, 2933094, Fax : +91-172-2565566

Unit-II :
Hill Top Industrial Estate, Jharmajri EPIP, Phase-I, (Extn.),
Bhatoli Kalan, Baddi (H.P.) 173205, India
Tel. : +91-1792-242100, 242101

Unit-V :
VENUS PHARMA GmbH
AM Bahnhof 1-3, D-59368,
Werne, Germany

